News
NextPharma Announces the Addition of a New Encapsulation/Over-encapsulation Machine
NextPharma the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotech industry, is pleased to announce that it has enhanced its Clinical Trials Services (CTS) facility in Göttingen,...
News
Thermo Fisher Scientific Completes Sales of Athena Diagnostics and Lancaster Laboratories
Thermo Fisher Scientific Inc., the world leader in serving science, has completed the previously announced sales of its two laboratory-testing services businesses, Athena Diagnostics and Lancaster Laboratories, in two separate transactions, resulting in total proceeds of $940 million....
News
Nycomed announces REACT study to evaluate impact of Daxas
Nycomed announced plans for an international phase III/IV study investigating the effect of Daxas® (500μg tablets, once daily) versus placebo on exacerbation rates in COPD patients who are concomitantly treated with fixed combination long-acting-ß2-agonists (LABA) and inhaled corticosteroids (ICS),...
News
APP Pharmaceuticals issues nationwide voluntary recall of Irinotecan Hydrochloride Injection
APP Pharmaceuticals, Inc., announced that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer. This recall is being conducted as a precautionary measure and there...
News
Lilly Announces New Vice President of Oncology Research
Eli Lilly and Company announced that Greg Plowman, M.D., Ph.D., will lead Lilly's oncology research efforts as the vice president, oncology research and senior vice president of ImClone Systems research. In this innovative new role created...
News
AstraZeneca initiates phase III clinical programme evaluating NKTR-118
AstraZeneca announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC). The Phase III clinical programme is designed to investigate the...
News
Takeda’s Donation to Aid Earthquake Relief Efforts in Japan
Takeda Pharmaceutical Company Limited announced 300 million Japanese yen donation to aid emergency relief for the earthquake on March 11, through The Japanese Red Cross Society, in view of the huge damages in the wide geographical area affected in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read